Literature DB >> 19498030

When is a predose a dose too much?

Tim Illidge, Yong Du.   

Abstract

Mesh：

Substances：

Year:  2009        PMID： 19498030     DOI： 10.1182/blood-2009-03-208918

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  2 in total

1.  Tumour targeting and radiation dose of radioimmunotherapy with (90)Y-rituximab in CD20+ B-cell lymphoma as predicted by (89)Zr-rituximab immuno-PET: impact of preloading with unlabelled rituximab.

Authors:  Kristoff Muylle; Patrick Flamen; Danielle J Vugts; Thomas Guiot; Ghanem Ghanem; Nathalie Meuleman; Pierre Bourgeois; Bruno Vanderlinden; Guus A M S van Dongen; Hendrik Everaert; Mélanie Vaes; Dominique Bron
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-03-20       Impact factor: 9.236

2.  [89Zr]Zr-cetuximab PET/CT as biomarker for cetuximab monotherapy in patients with RAS wild-type advanced colorectal cancer.

Authors:  E J van Helden; S G Elias; S L Gerritse; S C van Es; E Boon; M C Huisman; N C T van Grieken; H Dekker; G A M S van Dongen; D J Vugts; R Boellaard; C M L van Herpen; E G E de Vries; W J G Oyen; A H Brouwers; H M W Verheul; O S Hoekstra; C W Menke-van der Houven van Oordt
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-11-09       Impact factor: 9.236
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.